Tetracaine

• IUPAC: (2 - (dimethylamino ) ethyl ) -4 - ( butylamino) benzoate
• Latin: Tetracaine

• 94-24-6
• 136-47-0 (hydrochloride)

• N01BA03
• C05AD02
• D04AB06
• S01HA03

White to slightly yellowish waxy substance ( tetracaine )

Local anesthetic

Blockade of voltage-dependent sodium channels

• 41-46 ° C ( tetracaine )
• 147-150 ° C ( hydrochloride)

Risk

• 6 mg · kg -1 ( LD50, mouse, i.v., tetracaine )
• 300 mg · kg -1 ( LD50, Mouse, oral, tetracaine )
• 6 mg · kg -1 ( LD50, rat, i.v., tetracaine )
• 35 mg · kg -1 ( LD50, mouse, s.c hydrochloride )
• 70 mg · kg -1 ( LD50, mouse, i.p. hydrochloride)
• 6.6 mg · kg -1 ( LD50, mouse, i.v. hydrochloride)
• 4.5 mg · kg -1 ( LD50, rat, iv, hydrochloride)

Template: Infobox chemical / molecular formula search available

Tetracaine is used as a surface anesthetic to mucous membranes - used - for example, small interventions in the mouth or nose. The effect lasts for several hours. It is about ten times more potent than procaine, but also ten times more toxic, which is why the maximum single dose of 20 mg should not be exceeded in the application. In the case of wounds and a very rapid absorption takes place, so there is a risk of poisoning in overdose. Is used frequently, therefore, lidocaine, has the same mechanism of action.

Tetracaine was by employees of the I.G. Farben belonging Hoechster inking developed and was first marketed in 1931 under the name Pantocain as a means of " topical anesthesia ".